126.64
+0.50
+(0.40%)
As of 3:05:33 PM GMT+5:30. Market Open.
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
75,740
116,929
135,392
118,443
134,783
Cost of Revenue
7,179
7,179
3,678
1,610
328
Gross Profit
68,561
109,750
131,714
116,833
134,455
Operating Expense
1,648,700
1,452,716
1,450,905
1,377,615
966,047
Operating Income
-1,580,139
-1,342,966
-1,319,191
-1,260,782
-831,592
Net Non Operating Interest Income Expense
162,086
161,267
60,045
4,560
60,383
Pretax Income
-1,443,432
-1,060,787
-1,182,678
-1,219,951
-774,740
Tax Provision
-10,024
-10,024
--
--
-53,228
Net Income Common Stockholders
-1,433,408
-1,050,763
-1,182,678
-1,219,951
-721,512
Diluted NI Available to Com Stockholders
-1,433,408
-1,050,763
-1,182,678
-1,219,951
-721,512
Basic EPS
-6.58
-4.82
-6.63
-9.05
-5.22
Diluted EPS
-6.58
-4.82
-6.63
-9.05
-5.22
Basic Average Shares
217,890.86
218,073.72
218,073.72
134,769.68
138,128.81
Diluted Average Shares
217,890.86
218,073.72
218,073.72
134,769.68
138,128.81
Rent Expense Supplemental
--
360
--
--
85
Total Expenses
1,655,879
1,459,895
1,454,583
1,379,225
966,375
Net Income from Continuing & Discontinued Operation
-1,433,408
-1,050,763
-1,182,678
-1,219,951
-721,512
Normalized Income
-1,433,520.22
-1,124,736.31
-1,244,382
-1,256,248
-721,512
Interest Income
--
164,252
64,164
11,263
69,791
Interest Expense
765
1,584
2,892
5,323
8,154
Net Interest Income
162,086
161,267
60,045
4,560
60,383
EBIT
-1,442,667
-1,059,203
-1,179,786
-1,214,628
-766,586
EBITDA
-1,382,833
-994,181
-1,114,355
-1,170,697
-723,124
Reconciled Cost of Revenue
7,179
7,179
3,678
1,610
328
Reconciled Depreciation
59,834
58,160
58,267
35,637
35,244
Net Income from Continuing Operation Net Minority Interest
-1,433,408
-1,050,763
-1,182,678
-1,219,951
-721,512
Total Unusual Items Excluding Goodwill
113
74,679
61,704
36,297
--
Total Unusual Items
113
74,679
61,704
36,297
--
Normalized EBITDA
-1,382,946
-1,068,860
-1,176,059
-1,206,994
-723,124
Tax Rate for Calcs
0
0
--
--
0
Tax Effect of Unusual Items
0.78
705.69
--
--
--
3/31/2021 - 10/24/2003
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
ERIS.NS Eris Lifesciences Limited
1,381.30
-1.37%
NEULANDLAB.BO Neuland Laboratories Limited
12,950.00
+1.63%
BAJAJHCARE.NS Bajaj HealthCare Limited
622.45
+0.09%
VALIANTLAB.NS Valiant Laboratories Limited
95.24
+1.77%
PARMAX.BO Parmax Pharma Limited
39.06
-9.16%
BAJAJHCARE.BO Bajaj HealthCare Limited
624.55
+0.26%
SUVENPHAR.BO Suven Pharmaceuticals Limited
1,179.95
-1.44%
HIKAL.BO Hikal Limited
436.05
+0.69%
ANUHPHR.BO Anuh Pharma Limited
172.50
-0.69%
AARTIPHARM.BO Aarti Pharmalabs Limited
731.95
+2.06%